Home » Topics » Regulatory » EMA

EMA
RSS

EMA grants accelerated assessment to glecaprevir/pibrentasvir MAA

Jan. 25, 2017

European orphan drug designation for Therabron's CG-367 for bronchiolitis obliterans syndrome

Jan. 24, 2017

Gilead Sciences' MAA for sofosbuvir/velpatasvir/voxilaprevir validated by EMA

Jan. 23, 2017

EMA awards orphan designation to Abeona Therapeutics' ABO-101

Jan. 20, 2017

FDA, EMA accept Boehringer Ingelheim's BI-695501 for review

Jan. 19, 2017

EMA accepts for review MAA for KRN-23 in X-linked hypophosphatemia

Jan. 5, 2017

Abeona Therapeutics' ABO-201 granted orphan drug designation in Europe

Jan. 4, 2017

FDA accepts betrixaban NDA for priority review, EMA validates MAA

Dec. 27, 2016

JCAR-017 obtains FDA breakthrough therapy designation and EMA PRIME access

Dec. 21, 2016

CHMP grants positive opinion for Truxima

Dec. 20, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...